The new Boston laboratory offers advanced analytical testing services.
Sartorius Stedim Biotech (SSB) opened a new bioanalytical and biosafety testing laboratory on Nov. 10, 2016 in Boston, MA. The new laboratory offers advanced analytical testing services including antibody-dependent cell cytotoxicity, complement-dependent cytotoxicity, surface plasmon resonance assay platforms, cell-based assays, and enzyme-linked immunosorbent assays. The facility also includes biacore analytical instruments.
The Boston facility is approximately 9000 square feet, and will provide GMP-compliant in vitro and polymerase chain reaction (PCR)-based assays for the detection of adventitious agents. The new facility will be staffed by bioanalytical experts, including 15 scientists. At the opening ceremony, Reinhardt Vogt, member of SSB’s executive committee said, “Our new laboratory will offer customers the analytical expertise to help them accelerate entry into clinical phases. We chose Boston as the site for our laboratory because it is a premier biotech hub, enabling us to showcase our portfolio of bioanalytical and biosafety tests, as well as attract the best technical staff to continue our expansion here in the future.”
Source: Sartorius Stedim Biotech
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.